This article is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
25E-NBOH (also known as 2C-E-NBOH and NBOH-2C-E) is a derivative of the hallucinogen 2C-E and is a synthetic psychedelic substance of the phenethylamine chemical class. Phenethylamine's produce an array of visually-dominant and stimulating psychedelic effects when administered.
It was first developed by Martin Hansen at the University of Copenhagen in 2010 as a brain imaging agent, but has subsequently been sold as a designer drug, first being identified in Brazil in 2018 on seized blotter paper, as well as in several European countries. It acts as a potent serotonin receptor agonist with similar affinity to better-known compounds such as 25I-NBOMe at 5-HT2A and 5-HT2C receptors. Several related substances of the NBOH family, 25B, 25C, and 25I, were identified in 2016 by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
- Ettrup, A., Hansen, M., Santini, M. A., Paine, J., Gillings, N., Palner, M., ... & Knudsen, G. M. (2011). Radiosynthesis and in vivo evaluation of a series of substituted 11 C-phenethylamines as 5-HT 2A agonist PET tracers. European journal of nuclear medicine and molecular imaging, 38(4), 681-693.https://doi.org/10.1007/s00259-010-1686-8
- Machado, Y., Neto, J. C., Lordeiro, R. A., Alves, R. B., & Piccin, E. (2020). Identification of new NBOH drugs in seized blotter papers: 25B-NBOH, 25C-NBOH, and 25E-NBOH. Forensic Toxicology, 38(1), 203-215.https://doi.org/10.1007/s11419-019-00509-7
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2017) EMCDDA—Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA. https://doi.org/10.2810/430586